• Vaccine Name: V-LSG1 + V- LSG2
• Target Pathogen: Lassa Fever Virus
• Target Disease: Lassa fever
• Vaccine Ontology ID: VO_0004081
• Type: Vaccina virus
• Preparation: The sequence is derived from the Josiah strain of Lassa virus, isolated from a patient in Sierra Leone (Fisher-Hoch et al., 2000).
• Virulence:
• Description: V-LSG1 + V- LSG2 is a vaccinia viruses expressing the S-segment Lassa single glycoproteins V-LSG1 [containing residues 1 to 296] and V-LSG2 [with a deletion of residues 67 to 234] (Fisher-Hoch et al., 2000).

Monkey Response

• Host Strain: Rhesus
• Vaccination Protocol: All animals received a single vaccination consisting of 0.2 ml of vaccine given intradermally and simultaneously at four separate sites (each forearm and the lateral aspect of each thigh) at a dilution which delivered to each animal a total dose of 10^9 PFU. Each vaccine was administered in one arm and one leg on the ipsilateral side. All animals were challenged subcutaneously with 10^3 to 10^4 PFU of the Josiah strain of Lassa virus in 0.5 ml of phosphate-buffered saline within 36 to 700 days (Fisher-Hoch et al., 2000).
• Persistence: The latest day on which virus could be recovered from serum was day 14, and that from tissues was day 21. Evidence for persistence elsewhere in tissues or fluids in survivors could not be found by cocultivation of tissues taken up to 112 days following challenge. However, autopsy and biopsy material examined by RT-PCR revealed that viral RNA could be detected at least 112 days after challenge (Fisher-Hoch et al., 2000).
• Side Effects: None noted
• Efficacy: Although V-LSG1 and V-LSG2 do not provide sufficient protection by themselves, when used together the can provide protective immunity to primates. This means that both glycoproteins are independently important in Lassa virus protection (Fisher-Hoch et al., 2000).
• Description: Both of the monkeys vaccinated with V-LSG1 + V-LSG2 were protected when challenged Lassa virus (Fisher-Hoch et al., 2000).